Last reviewed · How we verify
Tralement
Tralement, marketed by American Regent, Inc., is a drug with a key composition patent expiring in 2028. The primary strength of Tralement lies in its established market presence, supported by its current marketing status. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Tralement |
|---|---|
| Also known as | manganese sulfate, zinc sulfate, copper sulfate, and selenious acid, trace elements (zinc sulfate, cupric sulfate, manganese sulfate and selenious acid) |
| Sponsor | American Regent, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety (PHASE4)
- Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tralement CI brief — competitive landscape report
- Tralement updates RSS · CI watch RSS
- American Regent, Inc. portfolio CI